Regeneron, Sanofi announce FDA accepts Dupixent sBLA for review
Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License ...
pharmaphorum11y
Sanofi plans to boost stake in Regeneron
Sanofi has announced its plans to buy more shares in US biotech, Regeneron Pharmaceuticals. The French drugmaker currently controls approximately 17% of Regeneron. Due to a long-term partnership ...
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU
The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...
Sanofi, Regeneron's Dupixent SBLA Accepted For FDA Review To Treat Chronic Spontaneous Urticaria
French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...
Hosted on MSN10mon
Regeneron (REGN), Sanofi's Dupixent Gets Label Update in US
Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced that the FDA has updated the label for Dupixent (dupilumab) for the indication of atopic dermatitis. Per the latest FDA update ...